Fig. 6
Antiangiogenic effects of plocabulin in tumor xenografts. a Tumor growth curve for mice bearing NCI-H460 lung xenografts and treated with placebo or plocabulin. Treatments were iniciated at a tumor volume size of ca. 150 mm3 and were intravenously administered at 0.08, 8 and 16 mg/kgfor three consecutive weeks (black arrows). Each point represents median values (n = 10). b Typical appearance of NCI-H460 lung xenografted tumors 4 days after the first administration of placebo or plocabulin (at 0.08, 8 and 16 mg/kg). c Evolution over the time of a tumor that achieved complete remission upon plocabulin treatment at 16 mg/kg .d Evaluation of vasculature in mice bearing NCI-H460 lung (n = 3/group) xenografts 24 h after the treatment with either placebo, 2 or 16 mg/kg of plocabulin (Angiosense™ 680 was dosed immediately after the treatment)